Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

029 Group SE M&A Activity 2004

Nov 3, 2004

4544_rns_2004-11-03_02f7cb25-246f-42ca-b1ab-76967c9783a4.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 3 November 2004 07:34

Rhein Biotech acquires the remaining 20% minority shares of its affiliate GCVC

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech acquires the remaining 20% minority shares of its affiliate GCVC in a combined transaction against four Korean vaccine products In a combined transaction Rhein Biotech acquires the remaining 20% minority shares of it’s Korean affiliate Green Cross Vaccines Corporation (GCVC) from Green Cross Corporation (GCC). In return, GCVC transfers the assets related to four Korean vaccine products, i.e. DTP, Japanese Encephalitis, Varicella and Hantavax to GCC. The transaction is effective November 3 for the share transfer and January 3, 2005 for the asset transfer. end of ad-hoc-announcement (c)DGAP 03.11.2004 ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 030734 Nov 04